Close

Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Bristol-Myers Squibb Company announced it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb’s CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma. Under the agreement, the two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination. If appropriate, the companies may conduct further development of the combination. This agreement represents an important cross-company collaboration exploring the potential role of this regimen in the treatment of metastatic melanoma.

Brian Daniels, senior vice president, Development and Medical Affairs, Bristol-Myers Squibb said, Metastatic melanoma is one of the most aggressive forms of cancer. We are excited to be working with Roche to evaluate the potential that together YERVOY and vemurafenib could improve outcomes for melanoma patients.

Latest stories

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back